Business ❯ Pharmaceutical Industry

Drug Approvals

FDA Approvals Obesity Drugs FDA Approval Rare Disease Treatments Market Competition Mounjaro

FDA Approves Teclistamab–Daratumumab Combination for Relapsed Multiple Myeloma After One Prior Therapy

The decision follows Phase 3 MajesTEC-3 results that showed an 83% lower risk of progression or death versus daratumumab-based regimens.